Treatment

Rocatinlimab clinical trials

6 indexed studies · 0 currently recruiting

Active not recruitingPHASE3
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
This study looks at the long-term effects of a new medicine, rocatinlimab, for teenagers and adults with moderate to severe eczema. It checks how safe and well-tolerated the medicine is, and if it continues to help over time.
For: Atopic Dermatitis
United States · Argentina · Australia
Active not recruitingPHASE2
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
This study is looking at a new medicine called rocatinlimab for people aged 18-75 with moderate to severe asthma. It wants to see if the medicine can reduce asthma attacks. Participants will receive either rocatinlimab or a dummy medicine called a placebo.
For: Asthma
United States · Argentina · Australia
Active not recruitingPHASE3
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
This study is testing a new medicine, rocatinlimab, for adults with prurigo nodularis. It's designed to see if the medicine can reduce itching and improve skin compared to a dummy medicine, to help people with this itchy skin condition.
For: Prurigo Nodularis
United States · Argentina · Australia
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
This study is looking at a new medicine called Rocatinlimab for adults with moderate to severe eczema. We want to see if it helps improve skin, reduce itching, and is safe over 24 weeks compared to a dummy medicine.
For: Atopic Dermatitis
Poland · Estonia · Denmark
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)
This study is testing a new medicine, rocatinlimab, for adults with moderate to severe eczema (atopic dermatitis). Researchers want to see if it helps reduce skin symptoms like itching and redness, compared to a dummy treatment, over 24 weeks.
For: Atopic Dermatitis
Poland · Netherlands · Portugal
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)
This study is looking into a new treatment called rocatinlimab for adults with moderate to severe eczema. It wants to see if this new medicine, when used with usual eczema creams, can help clear up skin and reduce itching compared to a dummy treatment.
For: Atopic Dermatitis
Italy · Netherlands · Slovakia

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)